Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Lineage switch in childhood acute leukemia: An unusual event with poor outcome

(2012) Jorge G. Rossi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement

(2010) C Bueno et al.   LEUKEMIA

Early lineage switch in an infant acute lymphoblastic leukemia

(2009) Hisano Sakaki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY